Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 18/20 | 0.42 |
| ▸ | F13A1 | P00488 | 2/20 | 0.41 |
| ▸ | TGM2 | P21980 | 2/20 | 0.41 |
| ▸ | TGM1 | P22735 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26081087 | 0.84 | GPR119 (0.41) | GPR119F13A1TGM2TGM1 | |
| SCHEMBL26081086 | 0.76 | IDH1 (0.43) | GPR119F13A1TGM2TGM1 | |
| SCHEMBL27196781 | 0.73 | SYK (0.45) | GPR119F13A1TGM2TGM1 | |
| SCHEMBL26081084 | 0.73 | MGLL (0.46) | GPR119 | |
| SCHEMBL22558920 | 0.73 | NPC1 (0.46) | GPR119 | |
| SCHEMBL16632037 | 0.73 | NPC1 (0.46) | GPR119 | |
| SCHEMBL30328109 | 0.72 | GPR119 (0.40) | GPR119F13A1TGM2TGM1 | |
| SCHEMBL30328592 | 0.72 | GPR119 (0.50) | GPR119 | |
| SCHEMBL12724291 | 0.71 | RPS6KB1 (0.48) | GPR119F13A1TGM2TGM1 | |
| SCHEMBL16651585 | 0.70 | IDO1 (0.41) | GPR119F13A1TGM2TGM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312522-A1 | CYP46A1 INHIBITORS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2023-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312522-A1 | CYP46A1 INHIBITORS AND METHODS OF USE THEREOF | CYP46A1, CYP26A1, CYP4A22 | GPR119 721/4885F13A1 3336/4885TGM2 1602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.